natgillin/translations-raw huggingface dataset:
Incidence of undesirable effects considered related to treatment with Nespo from controlled clinical studies are:
Pogostnost neželenih učinkov, ki veljajo za povezane z Nespom in so jih zabeležili v kontroliranih kliničnih študijah, so:
Incidence of undesirable effects considered related to treatment with Nespo from controlled clinical studies are:
Pogostnosti neželenih učinkov, ki veljajo za povezane z Nespom in so jih zabeležili v kontroliranih kliničnih študijah, so:
Incidence per 100 person-years (95% CI)
Incidenca na 100 človek-let (95-odstotni IZ)
Incidence rate of PHN per 1,000 person years
Delež pojavnosti PHN na 1.000 oseb-let
Incidence rate of zoster per 1,000 person years
Delež pojavnosti herpesa zostra na 1.000 oseb-let
Incidence rate per 100 patient- years*
Pojavnost na 100 bolnik- let
Incidence rate per 100 patient- years*
Pojavnost na 100 bolnik-let
Incidences (%)
Pojavnost (%)
Incision site haemorrhage
krvavitev na mestu incizije
Incision site infection
okužba na mestu vboda
Incision site infection
okužba na mestu vboda,
INCIVO acts against the virus that causes hepatitis C infection and is used to treat chronic hepatitis C infection in adult patients (aged 18–65 years) in combination with peginterferon alfa and ribavirin.
Zdravilo INCIVO deluje proti okužbi z virusom hepatitisa C in se v kombinaciji s peginterferonom alfa in ribavirinom uporablja za zdravljenje kronične okužbe z virusom hepatitisa C pri odraslih (starih 18–65 let).
INCIVO can be used for patients with chronic hepatitis C infection who have never been treated before or can be used in patients with chronic hepatitis C infection who have been treated previously with an interferon-based regimen.
Zdravilo INCIVO se uporablja pri bolnikih, okuženih z virusom hepatitisa C, ki še niso bili zdravljeni ali pri bolnikih, ki so se predhodno zdravili z interferonom.
INCIVO contains a substance called telaprevir and belongs to a group of medicines called ‘NS3-4A protease inhibitors’.
Zdravilo INCIVO vsebuje snov telaprevir in sodi v skupino zdravil, ki jih imenujemo ‘zaviralci NS3-4A proteaze’.
INCIVO contains sodium
Zdravilo INCIVO vsebuje natrij
INCIVO had no effects on fertility or fecundity when evaluated in rats.
Zdravilo INCIVO ni vplivalo na plodnost ali rodnost pri podganah.
INCIVO in combination with peginterferon and ribavirin is not recommended in patients with platelets < 90,000/mm3 and/or albumin < 3.3 g/dl.
Uporaba zdravila INCIVO v kombinaciji s peginterferonom in ribavirinom pri bolnikih s številom trombocitov < 90.000/mm3 in/ali koncentracijo albumina < 33 g/l ni priporočena.
INCIVO is available in packs containing 1 bottle (total of 42 film-coated tablets) or 4 bottles (total of 168 film-coated tablets).
Zdravilo INCIVO je na voljo v škatli z 1 plastenko (vsebuje 42 filmsko obloženih tablet) ali v škatli s 4 plastenkami (skupaj 168 filmsko obloženih tablet).
INCIVO is not for use in children or adolescents, because it has not been sufficiently studied in patients under 18 years of age.
Zdravilo INCIVO ni namenjeno uporabi pri otrocih ali mladostnikih, ker ni bilo zadostno preučeno pri bolnikih, mlajših od 18 let.
INCIVO is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C, score ≥ 7) or decompensated liver disease (ascites, portal hypertensive bleeding, encephalopathy, and/or jaundice other than Gilbert’s Syndrome, see section 4.4).
Uporaba zdravila INCIVO pri bolnikih z zmerno do hudo okvaro jeter (razred B ali C po Child-Pughu, ocena ≥ 7) ali z dekompenzirano boleznijo jeter (ascites, krvavitev iz varic zaradi portalne hipertenzije, encefalopatija, in/ali zlatenica, ki ni povezana z Gilberovim sindromom) ni priporočljiva (glejte poglavje 4.4).
Incivo is used to treat chronic (long term) hepatitis C (a disease of the liver due to infection with the hepatitis C virus) in combination with two other medicines, peginterferon alfa and ribavirin.
Zdravilo Incivo se uporablja za zdravljenje kroničnega (dolgotrajnega) hepatitisa C (bolezni jeter zaradi okužbe z virusom hepatitisa C) v kombinaciji z dvema drugima zdraviloma, peginterferonom alfa in ribavirinom.
INCIVO must always be taken together with food.
Zdravilo INCIVO morate vedno jemati skupaj s hrano.
INCIVO must be taken with peginterferon alfa and ribavirin to prevent treatment failure.
Za zagotavljanje uspeha zdravljenja, je treba zdravilo INCIVO jemati skupaj s peginterferonom alfa in ribavirinom.
INCIVO must be used in combination with peginterferon alfa and ribavirin.
Zdravilo INCIVO je treba uporabljati skupaj s peginterferonom alfa in ribavirinom.
INCIVO must not be administered concurrently with Class Ia or III antiarrhythmics, except for intravenous lidocaine.
Zdravila INCIVO ne smete predpisovati sočasno z antiaritmiki razreda Ia ali III (izjema je intravensko dani lidokain).
Incivo must not be given in combination with several other medicines, including those which are affected by or affect the CYP3A gene and Class Ia or III antiarrhythmics.
Zdravilo Incivo se ne sme jemati v kombinaciji z več drugimi zdravili, vključno s tistimi, na katera učinkujejo gen CYP3A in antiaritmiki razreda Ia ali III, oziroma tistimi, ki učinkujejo na gen CYP3A in antiaritmike razreda Ia ali III.
INCIVO must not be restarted if discontinued by your doctor.
Če zdravnik prekine vaše zdravljenje z zdravilom INCIVO, ga ne smete ponovno začeti jemati.
INCIVO must not be restarted if discontinued by your doctor.
Če zdravnik prekine zdravljenje z zdravilom INCIVO, ga ne smete več jemati.
INCIVO must not be restarted if discontinued by your doctor.
Če zdravnik prekine zdravljenje z zdravilom INCIVO, ga ne smete začeti ponovno jemati.
INCIVO must not be taken alone and must be taken in combination with peginterferon alfa and ribavirin to be sure your treatment works.
Za zagotavljanje učinkovitega zdravljenja, zdravila INCIVO ne smete jemati samega, vedno ga je treba jemati skupaj s peginterferonom alfa in ribavirinom.
INCIVO treatment completed
zaključek zdravljenja z zdravilom INCIVO
INCIVO with food and drink
Zdravilo INCIVO skupaj s hrano in pijačo
INCIVO, 1,125 mg (three 375 mg film-coated tablets) should be taken orally twice daily (b.i.d.) with food.
Zdravilo INCIVO v odmerku 1.125 mg (tri 375 mg filmsko obložene tablete) je treba jemati peroralno dvakrat na dan, s hrano.
INCIVO, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis):
Zdravilo INCIVO je v kombinaciji s peginterferonom alfa in ribavirinom indicirano za zdravljenje kroničnega hepatitisa C z genotipom 1 pri odraslih bolnikih s kompenzirano boleznijo jeter (vključno s cirozo):
include
Zelo pogosti
Included in Annex II for all food producing species
V dodatku II za vse živali za proizvodnjo živil
Included in the pack: a pre-filled syringe of Pegasys an injection needle
Vključeno v ovojnini: napolnjena injekcijska brizga z zdravilom Pegasys, injekcijska igla.
Included in the pack: a vial of Pegasys solution for injection
Vključeno v ovojnini: viala raztopine zdravila Pegasys za injiciranje.
Included in these studies were in total 402 subjects with BRAF V600E and 49 subjects with BRAF V600K mutation.
V te študije je bilo skupaj vključenih 402 bolnikov z mutacijo BRAF V600E in 49 bolnikov z mutacijo BRAF V600K.
Included patients who had ≥ 50 copies/mL in the Week 48 or 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Vključuje bolnike, ki so imeli v oknu 48. ali 96. tedna ≥ 50 kopij/ml; bolnike, ki so predčasno prekinili sodelovanje zaradi pomanjkanja ali izgube učinka, bolnike, ki so sodelovanje prekinili zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka in so imeli v času prekinitve virološko vrednost ≥ 50 kopij/ml.
Included patients who had ≥ 50 copies/mL in the Week 48 or Week 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Vključuje bolnike, ki so imeli v oknu 48. tedna ali 96. tedna ≥ 50 kopij/ml; bolnike, ki so predčasno prekinili sodelovanje zaradi pomanjkanja ali izgube učinka, bolnike, ki so sodelovanje prekinili zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka in so imeli v času prekinitve virološko vrednost ≥ 50 kopij/ml.
Included patients who had ≥ 50 copies/mL in the Week 48 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Vključuje bolnike, ki so imeli v oknu 48. tedna ≥ 50 kopij/ml; bolnike, ki so predčasno prekinili sodelovanje zaradi pomanjkanja ali izgube učinka, bolnike, ki so sodelovanje prekinili zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka in so imeli v času prekinitve virološko vrednost ≥ 50 kopij/ml.
Includes 15% of subjects with previous history of HPV disease/infection
Vključuje 15 % preiskovank z anamnezo bolezni/okužbe s HPV
Includes clinical vertebral fractures and non-vertebral fractures.
Vključuje klinične zlome vretenc in nevretenčne zlome.
Includes clinical vertebral, hip, forearm, and humerus fractures, as defined by the WHO.
Vključuje klinične zlome vretenc, kolka, podlakta in nadlahtnice, kot jih opredeljuje Svetovna zdravstvena organizacija.
Includes patients co-infected with human immunodeficiency virus (HIV) and patients with recurrent HCV post-liver transplant (see section 4.4.).
Vključno z bolniki, ki imajo sočasno okužbo z virusom človeške imunske pomanjkljivosti (HIV), in bolniki s ponovno okužbo s HCV po presaditvi jeter (glejte poglavje 4.4.).
Includes patients who did not receive ENF and those who were previously treated with and continued ENF
Vključuje bolnike, ki niso prejeli ENF, in tiste, ki so se predhodno zdravili z ENF in njegovo jemanje nadaljevali.
Includes patients who discontinued due to adverse event or death at any time point from day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
Vključuje bolnike, ki so prenehali sodelovati zaradi neželenih učinkov ali smrti, kadar koli od 1. dne do konca časovnega okna, če zaradi tega v določenem oknu ni bilo viroloških podatkov o zdravljenju.
Includes patients who discontinued due to adverse event or death at any time point from day 1 through the week 24 window resulting in no virologic data on treatment during the specified window.
Vključuje bolnike, ki so prenehali sodelovati zaradi neželenih učinkov ali smrti, kadar koli od 1. dne do konca časovnega okna 24. tedna, če zaradi tega v določenem oknu ni bilo viroloških podatkov o zdravljenju.
Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
Vključuje bolnike, ki so prenehali sodelovati zaradi neželenih učinkov ali smrti, kadar koli od 1. dne do časovnega okna, če zaradi tega v določenem oknu ni bilo viroloških podatkov o zdravljenju.
Includes patients who discontinued due to an AE or death at any time point from day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
Vključuje bolnike, ki so prenehali sodelovati zaradi neželenih učinkov ali smrti, kadar koli od 1. dne do konca časovnega okna, če zaradi tega v določenem oknu ni bilo viroloških podatkov o zdravljenju.
Includes patients who discontinued for reasons other than an adverse event, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.
Vključuje bolnike, ki so sodelovanje prekinili zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.
Vključuje bolnike, ki so sodelovanje prekinili zaradi drugih razlogov kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.
Vključuje bolnike, ki so sodelovanje prekinili zaradi drugih razlogov kot so neželeni učinki, smrt ali pomanjkanje ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
Includes patients who discontinued for reasons other than an AE, death, or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.
Vključuje bolnike, ki so sodelovanje prekinili zaradi drugih razlogov kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
Includes patients who had HIV-1 RNA ≥ 50 copies/mL in the week 24 window, patients who discontinued early due to lack or loss of efficacy, patients who discontinued for reasons other than an adverse event or death, and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Vključuje bolnike, ki so imeli v oknu 24. tedna HIV-1 RNA ≥ 50 kopij/ml, bolnike, ki so predčasno prekinili sodelovanje zaradi pomanjkanja ali izgube učinka, bolnike, ki so sodelovanje prekinili zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje oz. izguba učinka, in so imeli v času prekinitve virološko vrednost ≥ 50 kopij/ml.
Includes patients who received at least one dose of blinded medicinal product after randomisation.
Zajema bolnike, ki so prejeli vsaj en odmerek prikritega zdravila po naključni razvrstitvi.
Includes pelvis, distal femur, proximal tibia, ribs, proximal humerus, forearm, and hip.
Vključuje zlome medenice, distalne stegnenice, proksimalne golenice, reber, proksimalne nadlahtnice, podlakta in kolka.
Includes relapsers, partial and null reponders to prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin.
Vključuje bolnike s ponovitvijo bolezni, bolnike z delnim odzivom ali brez odziva na predhodno zdravljenje z interferonom (pegiliranim ali nepegiliranim), z ribavirinom ali brez ribavirina.
Includes relapsers, partial and null responders to prior treatment with peginterferon and ribavirin.
Vključuje bolnike s ponovitvijo bolezni, bolnike z delnim odzivom ali brez odziva na predhodno zdravljenje z peginterferonom in ribavirinom.
Includes subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.
Vključuje osebe, ki so sodelovanje prekinile zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
Includes subjects who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.
Vključuje osebe, ki so sodelovanje prekinile zaradi razlogov, ki niso bili neželeni učinki, smrt ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
Includes subjects who had ≥ 50 copies/mL in the Week 48 or Week 144 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Vključuje osebe, ki so imele v oknu 48. ali 144. tedna ≥ 50 kopij/ml, osebe, ki so predčasno prekinile sodelovanje zaradi pomanjkanja ali izgube učinka, osebe, ki so sodelovanje prekinile zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje oz. izguba učinka in so imele v času prekinitve virološko vrednost ≥ 50 kopij/ml.
Includes subjects who had ≥ 50 copies/mL in the week 48 or week 96 window, subjects who discontinued early due to lack or loss of efficacy, subjects who had a viral load ≥ 50 copies/mL at time of change in background regimen, subjects who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral load of ≥ 50 copies/mL.
Vključuje osebe, ki so imele v oknu 48. ali 96. tedna ≥ 50 kopij/ml, osebe, ki so predčasno prekinile sodelovanje zaradi pomanjkanja ali izgube učinka, osebe, ki so imele virusno obremenitev ≥ 50 kopij/ml v času spremembe osnovnega režima, osebe, ki so sodelovanje prekinile zaradi razlogov, ki niso bili neželeni učinki, smrt ali pomanjkanje oz. izguba učinka, in so imele v času prekinitve virološko obremenitev ≥ 50 kopij/ml.
Includes three non-virological failures and four unconfirmed virological failures.
2.Vključuje tri nevirusne neuspehe in štiri nepotrjene virusne neodzive.
Includes vertebral and non-vertebral fractures
zajema vertebralne in nevertebralne zlome
Includes vertebral and non-vertebral fractures
zajema vertebralne in nevertebralne zlome;
Includes ‘Need for lung transplantation or atrial septostomy’ (1 patient on selexipag and 2 on placebo)
Vključuje 'potrebo po presaditvi pljuč ali atrijski septostomiji' (1 bolnik na seleksipagu in 2 na placebu)
Includes: alcohol (42 % v/v see leaflet), high fructose corn syrup, propylene glycol, glycerol, polyoxyl 40 hydrogenated castor oil, potassium (as acesulfame potassium).
Vsebuje: alkohol (42% v/v, glejte navodilo za uporabo), visokofruktozni koruzni sirup, propilenglikol, glicerol, makrogolglicerol 40 hidrogenirano ricinusovo olje , kalij (kot kalijev acesulfamat).
Includes: contusion, ecchymosis, penile haemorrhage, and injection site haemorrhage.
Vključuje: kontuzijo, ekhimoze, krvavitev penisa in krvavitev na mestu injiciranja.
Includes: injection site haematoma and penile haematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of patients.
Vključuje: o hematomu na mestu injiciranja in hematomu penisa so poročali z dobesednim izrazom modrica penisa ali modrica na mestu injiciranja pri 87 % bolnikov.
Includes: injection site pain, penile pain, and injection site discomfort.
Vključuje: bolečino na mestu injiciranja, bolečino penisa in nelagodje na mestu injiciranja.
Includes: injection site swelling, penile oedema, penile swelling, local swelling, scrotal swelling, and injection site oedema.
Vključuje: oteklino na mestu injiciranja, edem penisa, oteklino penisa, lokalno oteklino, oteklino skrotuma in edem na mestu injiciranja.
including coma.
vključno s komo.
including constipation
Pankreatitis11
including data for only those patients who are candidates for
podatki o bolnikih, ki so primerni za zdravljenje z zdravilom
Including enterocolitis infectious.
d vključuje infekcijski enterokolitis
Including inhibited larvae
vključno z inhibiranimi ličinkami
including pyelonephritis3
sečil, vključno s pielonefritisom3
including sepsisa
vključno s sepsoa
including severe
vključno s hudo
including some fatal
vključno z nekaj
including tooth extraction
tudi izdrtje zob
including tooth extraction
vključno z ekstrakcijo zoba
Including tooth extraction.
vključno z izdrtjem zoba
including VEGF or its downstream receptors.
vključno z VEGF ali njihovih posledičnih receptorjev.
Inclusion criteria: to meet criteria based on SmPC indication.
Vključitveni kriteriji: izpolnjevanje kriterija, ki temelji na indikaciji iz Povzetka glavnih značilnosti zdravila.
incoherence, loss of consciousness, coma, stupor, convulsions, cerebrovascular accident, encephalopathy
inkoherenca, izguba zavesti, koma, stupor, krči, cerebrovaskularni dogodek, encefalopatija
incoherent speech
nepovezano govorjenje,
Incompatibilities
4 (10,8%)
Incompatibilities
6.2. Inkompatibilnosti
Incompatibilities
Glavne inkompatibilnosti
Incompatibilities
Glavne inkopatibilnosti
Incompatibilities
Inkompatibilnost
Incompatibilities
Inkompatibilnosti.
Incompatibilities
Ósamrýmanleiki
Incompatibilities:
Inkompatibilnost
Incompatibilities: None known.
Inkompatibilnosti Niso znane.
Incompatibility of some prefilled glass syringes (including Rapilysin) with certain needle free connectors has been reported.
Poročali so o inkompatibilnosti med nekaterimi napolnjenimi steklenimi injekcijskimi brizgami (vključno z zdravilom Rapilysin) in nastavki brez igel.
Incompatible concentrations
Nezdružljive koncentracije
Incomplete primary immunization (adults)
Nezaključena primarna imunizacija (odrasli)
Incontinence
inkontinenca
incontinence (lack of control) of urine, frequent passing of urine, inability to pass urine, pain when passing urine
uhajanje (nezmožnost nadzora) urina, pogosto uriniranje, nezmožnost uriniranja, bolečine ob uriniranju
incontinence (lack of control) of urine, frequent passing of urine, pain when passing urine
uhajanje urina (nezmožnost nadzora), pogosto uriniranje, bolečine pri uriniranju
Incontinence (stools)
inkontinenca (blata)
Incontinence (stools).
inkontinenca (blata)
Incontinence Episode Frequency: In all four studies the duloxetine-treated group had a 50% or greater median decrease in IEF compared with 33% in the placebo-treated group.
Pogostnost inkontinenčnih epizod: v vseh štirih študijah je imela skupina, zdravljena z duloksetinom, 50 % ali večje mediano znižanje IEF v primerjavi s 33 % v skupini, ki je prejemala placebo.
Incontinence impact
Vpliv inkontinence
incontinence,
ogrožujoči (stopnja
Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity.
Vgrajevanje v DNA in RNA lahko prispeva tudi k citotoksičnosti citarabina.
Incorporation of 25 mg active substance per kg feed with:
Dodajanje 25 mg zdravilne učinkovine/kg krme:
Incorrect use of the transfer device will result in loss of vacuum and prevent transfer of the solvent, thereby prolonging or preventing reconstitution of Respreeza.
Nepravilna uporaba pripomočka za prenos povzroči izgubo vakuuma in prepreči prenos vehikla, kar podaljša ali prepreči rekonstitucijo zdravila Respreeza.
Increase
povečanje
increase astemizole and terfenadine
astemizola in terfenadina.
Increase at two-weekly intervals in increments of 1 mg/kg
dvotedenskih intervalih po največ 1 mg/kg
increase dihydroergotamine,
dihidroergotamina, ergonovina,
increase dose if clinically indicated.
potrebna; povečajte odmerek, če je klinično indicirano.
Increase dose to: 2.3 mg/kg body weight
Povečajte odmerek na: 2,3 mg/kg telesne teže
Increase dose to: 2.4 mg/kg body weight
Povečajte odmerek na: 2,4 mg/kg telesne teže
increase halofantrine and
Cmax karbamazepina skupno
increase if co-administered with
Pri sočasni uporabi
Increase in
dasabuvirju je
Increase in
lahko posledica
Increase in
Večja
increase in
zvečanje
increase in a type of white blood cells called eosinophils infusion site reaction (a reaction of the skin area where the infusion drip was inserted)
povečanje vrste belih krvnih celic, imenovanih eozinofilci reakcija na mestu infundiranja (reakcija na predelu kože, kjer je bila vstavljena kapalna infuzija)
Increase in amylase
povečane vrednosti amilaze
increase in an enzyme called amylase a failure of the bone marrow to produce new red blood cells (pure red cell aplasia)
zvišanje encima, imenovanega amilaza. nezmožnost kostnega mozga za tvorbo novih rdečih krvnih celic (čista aplazija rdečih celic).
increase in an enzyme called lactate dehydrogenase clotting in vein at injection-site; inflammation at injection-site; pain at injection-site; collection of fluid in your body
povečana vrednost encima laktat-dehidrogenaze strjevanje krvi v veni na mestu injiciranja, vnetje na mestu injiciranja, bolečina na mestu injiciranja, kopičenje tekočine v telesu
Increase in AUC, Cmax and Tmax for Nelfinavir in Fed State Relative to Fasted State Following 1250 mg VIRACEPT (5 x 250 mg tablets)
Povečanje AUC, Cmax in Tmax nelfinavirja po obroku v primerjavi z uživanjem zdravila na tešče po 1250 mg odmerku zdravila VIRACEPT (5 x 250 mg tablete)
increase in bilirubin (a substance produced by the liver)
zvišanje vrednosti bilirubina (substanca, ki nastaja v jetrih),